Rethinking drug design in the AI era
- IPW
- Highlights
In a Perspective in Nature Reviews Drug Discovery, Gisbert Schneider and a diverse group of international experts discuss the ‘grand challenges’ in small-molecule drug discovery with artificial intelligence (AI) and the approaches to address them.
The Mix of Mind & Machine – Image courtesy of Jack Burgess, Jack Burgess Studios.
Reference
Schneider P., Walters W., Plowright A., Sieroka N., Listgarten J., Goodnow R., Fisher J., Jansen J., Duca J., Rush T., Zentgraf M., Hill J., Krutoholow E., Kohler M., Blaney J., Funatsu K., Luebkemann C., Schneider G.
Rethinking drug design in the artificial intelligence era.
Nat Rev Drug Discov (2019) doi:external page 10.1038/s41573-019-0050-3